lenalidomide has been researched along with Lymphoma of Mucosa-Associated Lymphoid Tissue in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Chen, Y; Gao, J; Jia, Y; Tao, H; Wang, F; Wu, P; Zhou, Z | 1 |
| Bonomini, L; Devizzi, L; Domènech, ED; Esposito, F; Ferreri, AJM; Guillermo, AL; Kiesewetter, B; Mannina, D; Merli, M; Pirosa, MC; Raderer, M; Salar, A; Sassone, M; Tucci, A; Visco, C; Zucca, E | 1 |
| Gong, D; Huang, W; Wang, Z; Yin, S; Zhou, K | 1 |
| Hu, X; Wang, Z; Yuan, S; Zhao, Y | 1 |
| Dolak, W; Kiesewetter, B; Kornauth, C; Lukas, J; Mayerhoefer, ME; Raderer, M; Simonitsch-Klupp, I | 1 |
| Thieblemont, C | 1 |
| Arcaini, L; Defrancesco, I | 1 |
| Alhyari, L; Cherry, M; Ibrahimi, S; Mukherjee, S; Scordino, T; Vidal, G | 1 |
| He, W; Min, X; Yang, X | 1 |
| Cabeçadas, J; Flinn, IW; Fogliatto, LM; Fowler, NH; Fustier, P; Gribben, JG; Hong, X; Izutsu, K; Kalambakas, S; Leonard, JP; Liu, D; Moreira, C; Nowakowski, GS; Offner, F; Pinto, A; Re, F; Scheinberg, P; Scheliga, A; Trneny, M; Wu, C; Zhang, H; Zhu, J | 1 |
| Kiesewetter, B; Lamm, W; Mayerhoefer, ME; Neuper, O; Raderer, M; Simonitsch-Klupp, I | 1 |
| Dolak, W; Kiesewetter, B; Mayerhoefer, ME; Raderer, M; Simonitsch-Klupp, I; Troch, M | 1 |
| Egle, A; Greil, R; Kiesewetter, B; Mayerhoefer, ME; Melchardt, T; Neumeister, P; Raderer, M; Simonitsch-Klupp, I; Voskova, D; Willenbacher, E; Willenbacher, W | 1 |
| Dolak, W; Kiesewetter, B; Lukas, J; Müllauer, L; Raderer, M; Troch, M; Zielinski, CC | 1 |
| Crane, E; List, A | 1 |
4 review(s) available for lenalidomide and Lymphoma of Mucosa-Associated Lymphoid Tissue
| Article | Year |
|---|---|
Coexistence of primary mediastinal MALT lymphoma and multiple myeloma like POEMS syndrome: A case report and literature review.
Topics: Bortezomib; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; POEMS Syndrome; Rituximab; Thymus Neoplasms | 2023 |
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Splenic Neoplasms; Survival Rate; Thalidomide | 2017 |
Overview on the management of non-gastric MALT lymphomas.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Chemoradiotherapy; Doxycycline; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Rituximab | 2018 |
Immunomodulatory drugs.
Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Myelodysplastic Syndromes; Neovascularization, Pathologic; T-Lymphocytes; Thalidomide | 2005 |
4 trial(s) available for lenalidomide and Lymphoma of Mucosa-Associated Lymphoid Tissue
| Article | Year |
|---|---|
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Treatment Outcome | 2023 |
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Placebos; Rituximab | 2019 |
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Rituximab; Thalidomide | 2017 |
A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma).
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; Thalidomide; Treatment Outcome | 2013 |
7 other study(ies) available for lenalidomide and Lymphoma of Mucosa-Associated Lymphoid Tissue
| Article | Year |
|---|---|
Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Gastroscopy; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome; Ultrasonography | 2022 |
Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.
Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Immunologic Factors; Lenalidomide; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Rituximab | 2020 |
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cerebrosides; Female; Humans; Immunohistochemistry; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Thalidomide; Treatment Outcome | 2018 |
Sustained response to lenalidomide for early relapsed marginal zone lymphoma.
Topics: Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Lymph Nodes; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neck; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphadenopathy; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Parotid Gland; Positron Emission Tomography Computed Tomography; Rituximab; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2018 |
Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Austria; Drug Evaluation; Female; Follow-Up Studies; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Retrospective Studies; Treatment Outcome | 2019 |
Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Remission Induction; Retrospective Studies; Thalidomide; Treatment Outcome | 2016 |